Baxter faces EU antitrust worries; Medicare cuts could hamper dialysis dollars;

 @FierceMedDev: Europe tables vote on tougher device regs. More | Follow @FierceMedDev

 @MarkHFierce:  We want your FMD Fierce 15 nominations. Send them in! More | Follow @MarkHFierce

 @DamianFierce: Theragenics has signed a deal to get its brachytherapy products on the market in the EU. Story | Follow @DamianFierce

 @MichaelGFierce: ICYMI: Avanir drops $110M on novel inhaled-delivery migraine device. Article | Follow @MichaelGFierce

> The FDA and the American Academy of Ophthalmology will sponsor a workshop on Oct. 11 designed to find ways to bring optical medical devices to market more quickly. Item

> Baxter ($BAX) reportedly is offering a number of concessions to the European Commission to ease antitrust concerns over its planned $4 billion merger with the Swedish dialysis company Gambro. Item

> CorMedix won a CE mark for its Neutrolin catheter lock, designed to cut the risk of bloodstream infections. More

> Seeking Alpha wrote a bullish piece on Nanosphere ($NSPH), a maker of molecular diagnostics that rely on gold nanoparticles. Item

> Makers of dialysis machines could see a 9.4% cut in Medicare payments--fallout from federal deficit-cutting efforts. Story

Biotech News

 @FierceBiotech:  SEC hunting down traders who made a quick killing on Onyx shares. Report | Follow @FierceBiotech

 @JohnCFierce:  Orexo stakes out $500M market for new opioid-addiction drug. More | Follow @JohnCFierce

 @RyanMFierce:  Xoma staffers form biotech startup to advance blood pressure med. News | Follow @RyanMFierce

 @EmilyMFierce:  In case you missed it over the holiday... Scientists create first regulatory map of tuberculosis. Report | Follow @EmilyMFierce

> Scientists score stem-cell victory with lab-grown liver tissue. Story

> Sarepta readies $125M raise to back muscular dystrophy drug work. Item

> Belgian biotech Cardio3 completes modest IPO. More

Pharma News

 @FiercePharma:  FDA to update generic labeling rules. Article | Follow @FiercePharma

 @CarlyHFierce: ICYMI: Glass particles trigger another Fresenius Kabi recall. Story | Follow @CarlyHFierce

>  Novartis' Lucentis gets its fourth approval in EU. News

> Orexo gets FDA approval for opioid addiction-fighting Zubsolv. Story

> Fresenius gets warning letter for India plant. More

Vaccines News

> Reliance on NIH threatens HIV vaccine funding. Story

> Polio discovery prompts Israeli vaccination push. More

> Merck KGaA: Lung cancer vaccine not dead. Article

> Study: Use of 2D barcodes could save healthcare $300M. News

> Novartis and Sanofi nab DoD vaccine contracts. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.